Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.
about
Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assemblyResistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical ImplicationsNew era for management of chronic hepatitis C virus using direct antiviral agents: A reviewDirect acting antivirals for the treatment of chronic viral hepatitisThe Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease InhibitorsHCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors2-octynoic acid inhibits hepatitis C virus infection through activation of AMP-activated protein kinaseComparative molecular dynamics simulation of Hepatitis C Virus NS3/4A protease (Genotypes 1b, 3a and 4b) predicts conformational instability of the catalytic triad in drug resistant strainsMericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study.Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents.Analysis of functional differences between hepatitis C virus NS5A of genotypes 1-7 in infectious cell culture systems.Canine hepacivirus NS3 serine protease can cleave the human adaptor proteins MAVS and TRIF.Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations.Inhibition of hepatitis C virus production by aptamers against the core protein.Production and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1-6.EPSTI1 Is Involved in IL-28A-Mediated Inhibition of HCV InfectionAdaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant.Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains.Genotypic distribution and hepatic fibrosis among HIV/HCV co-infected individuals in Southern China: a retrospective cross-sectional studyThe NS4A Cofactor Dependent Enhancement of HCV NS3 Protease Activity Correlates with a 4D Geometrical Measure of the Catalytic Triad Region.Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells.Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor ResistanceNaturally occurring mutations to HCV protease inhibitors in treatment-naïve patients.Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system.Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.Inhibition of hepatitis C virus infection by DNA aptamer against envelope protein.Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents.Adapted J6/JFH1-based Hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor.Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance.A novel strategy to develop a robust infectious hepatitis C virus cell culture system directly from a clinical isolateDrug therapy: telaprevir.Hepatitis C therapy in non-genotype 1 patients: the near future.Telaprevir/boceprevir era: from bench to bed and back.Optimal treatment with boceprevir for chronic HCV infection.Treatment decisions and contemporary versus pending treatments for hepatitis C.Is genotype 3 of the hepatitis C virus the new villain?Hepatitis C virus resistance to new specifically-targeted antiviral therapy: A public health perspective.NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety.Hepatitis C Virus NS4B Can Suppress STING Accumulation To Evade Innate Immune Responses
P2860
Q24297412-858E0835-BC4B-44C5-A84D-E7F91F9ACB1EQ26777408-D928C551-82CE-49A9-BC7C-42988203C8A5Q26800050-3D391888-C803-44E4-8454-9856BFAD57F3Q27022216-E5D62636-A488-44F4-903B-3606B528CFACQ27671640-4FBD69E0-AE0F-42B2-B10A-08A74D3519C0Q28481038-3476606E-7BC4-431A-917D-7B9E5D74A649Q28533471-120B2EF0-18FC-42FD-A3EC-2AEACC76CD93Q28541762-92A0C608-D577-4845-B688-1DC7AA4E1035Q34040906-30B1DDDF-CF87-48F0-8A3A-56BD60FA1F2DQ34057584-3EC83705-19A9-4ECA-A3D8-350702572515Q34288777-53966E63-CD04-4B95-8324-570A7D4AC797Q34369535-3F4FA50C-C11C-4631-8B39-EBEB0C53F26AQ34599453-C57DA83E-9504-4643-91DA-064B776329A7Q35059404-BC2F71C5-CB8C-457B-AE63-81EC02F040E5Q35557533-437B1DED-C807-4201-A26B-E9D29D39814DQ35749502-6452BB03-41AC-4808-8E06-5CCB8A012737Q35861270-161CC0AE-95F3-485D-8D1C-7C5D9D917F3EQ35935502-EA45A0D7-2084-4D57-9354-1E4F4BB648EEQ36110233-E4C17B9A-5896-4A85-A168-6BB71C0752CDQ36218266-0FB5855F-A301-48F5-963D-0B1291509D9CQ36276817-1B512263-DAAC-4377-8F79-5541BDBE7BE2Q36290778-0E4CDB8B-CD81-456C-B227-C377682E05A3Q36384127-F84D67B1-4DC4-4D07-B68C-9F2B77DFC1ABQ36438628-0EF744CC-4C63-46D7-BDB6-E341F5B7E129Q36667066-4E803DBD-4318-4621-BB9F-41FF3DCC9B28Q36933403-E8898E12-2E96-4EC2-A510-C2A16681B97DQ37263829-A1D9EF38-B745-4604-A5C0-4511E934D695Q37310564-949F4082-FAC0-48F8-BB1B-33CC0C4B3919Q37335699-9B9EE177-B077-480C-A2C6-5F39100AD85CQ37336496-767F16E3-1C42-4199-9349-5913CCC9EF86Q37547199-1DDD21A1-8443-4831-AD0A-A6D25C5B820BQ37928563-803BD0D5-55F8-40F8-817B-B270BF03E015Q38023869-87B2F1A2-BA67-4977-BC3C-879C4B880C01Q38062524-92D46C1F-00ED-48BC-834B-A5681A17C297Q38071383-66001B38-3C29-4C9C-9E4C-2C9E97F1D1E0Q38135774-52B538F7-9E92-41A4-8E6E-DCBAF4A38D3AQ38155123-6DF95D4F-6104-4274-B4DC-17B7D440A868Q38156875-D5A5701B-6827-494A-8DC7-2E4ABAE0680CQ38215505-D4D3EEF0-AC8D-4238-B842-F4149B2C9988Q38827808-D0DFEB6A-F670-48DA-A07A-0A20E67AAE8D
P2860
Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Differential efficacy of prote ...... protease recombinant viruses.
@en
Differential efficacy of prote ...... protease recombinant viruses.
@nl
type
label
Differential efficacy of prote ...... protease recombinant viruses.
@en
Differential efficacy of prote ...... protease recombinant viruses.
@nl
prefLabel
Differential efficacy of prote ...... protease recombinant viruses.
@en
Differential efficacy of prote ...... protease recombinant viruses.
@nl
P50
P1433
P1476
Differential efficacy of prote ...... A protease recombinant viruses
@en
P2093
Lubna Ghanem
Tanja B Jensen
P304
P356
10.1053/J.GASTRO.2011.06.004
P407
P577
2011-06-12T00:00:00Z